Phosphate and calcium are required for TGFbeta-mediated stimulation of ANK expression and function during chondrogenesis.
The expression of ANK, a key player in biomineralization, is stimulated by treatment with TGFbeta. The purpose of this study was to determine whether TGFbeta stimulation of ANK expression during chondrogenesis was dependent upon the influx of calcium and phosphate into cells. Treatment of ATDC5 cells with TGFbeta increased ANK expression during all phases of chondrogenic differentiation, particularly at day 14 (proliferation) and day 32 (mineralizing hypertrophy) of culture. Phosphate uptake studies in the presence and absence of phosphonoformic acid (PFA), a competitive inhibitor of the type III Na(+)/Pi channels Pit-1 and Pit-2, indicated that the stimulation of ANK expression by TGFbeta required the influx of phosphate, specifically by the Pit-1 transporter, at all phases of differentiation. At hypertrophy, when alkaline phosphatase is highly expressed, inhibition of its activity with levamisole also abrogated the stimulatory effect of TGFbeta on ANK expression, further illustrating that Pi availability and uptake by the cells is necessary for stimulation of ANK expression in response to TGFbeta. Since previous studies of endochondral ossification in the growth plate have shown that L-type calcium channels are essential for chondrogenesis, we investigated their role in the TGFbeta-stimulated ANK response in ATDC5 cells. Treatment with nifedipine to inhibit calcium influx via the L-type channel Cav1.2 (alpha(1C)) inhibited the TGFbeta stimulated increase in ANK expression at all phases of chondrogenesis. Our findings indicate that TGFbeta stimulation of ANK expression is dependent upon the influx of phosphate and calcium into ATDC5 cells at all stages of differentiation.
Oca
Paulina
P
Center for Translational Medicine, Department Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Zaka
Raihana
R
Dion
Arnold S
AS
Freeman
Theresa A
TA
Williams
Charlene J
CJ
D000469:Alkaline Phosphatase / Q000037:antagonists & inhibitors / Q000378:metabolism; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D020746:Calcium Channels, L-Type / Q000378:metabolism; D020219:Chondrogenesis / Q000187:drug effects*; D007150:Immunohistochemistry; D028061:Phosphate Transport Proteins / Q000235:genetics / Q000378:metabolism*; D010710:Phosphates / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D034421:Sus scrofa; D050817:Transcription Factor Pit-1 / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
D020746:Calcium Channels, L-Type; D028061:Phosphate Transport Proteins; D010710:Phosphates; D050817:Transcription Factor Pit-1; D016212:Transforming Growth Factor beta; D000469:Alkaline Phosphatase; D002118:Calcium